Tomorrow’s Medical Cannabis Track Keynote Talk—Day 2
September 14—Baltimore, Maryland—Dr. Denise Vidot, University of Miami, will give a keynote talk tomorrow in the medical cannabis meeting room 314–315 at 10:50 a.m. The talk is titled “Cannabinoids and the Brain-Heart-Gut Axis: Informing Science from an Epidemiological Lens.”
Dr. Denise Vidot, University of Miami, will give a keynote talk tomorrow in the medical cannabis meeting room 314–315 at 10:50 a.m. The talk is titled “Cannabinoids and the Brain-Heart-Gut Axis: Informing Science from an Epidemiological Lens.”
Animal and clinical research have demonstrated how cannabinoids can influence health via the endocannabinoid system, more recently referred to as the endocannabinoidome. This session will focus on how the field of epidemiology, the study of the distribution and determinants of health-related states and events in specified populations, can be applied to inform cannabis science. Specifically, Dr. Vidot will begin by highlighting the current state of research on the impact of cannabis on the brain, heart, and gut independently; then she will discuss her laboratory’s epidemiologic evidence-based hypotheses regarding how cannabis engages with the brain-heart-gut axis to impact multiple chronic diseases. Data will be shared from ongoing and completed studies funded by the National Institutes of Health and University of Miami.
Dr. Denise C. Vidot is a cannabis epidemiologist at the University of Miami where she is founder of the International Cannabis Research Collaborative. Her research focuses on the biological, psychosocial, and societal implications of cannabis by providing evidence on the impact of phytocannabinoids on human health via the endocannabinoid system.
For more information on the medical cannabis track, please visit the 2021 Cannabis Science Conference East Final Program & Exhibitor Guide.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
